Lead Plaintiff Deadline: 02/14/2020
SUMMARY OF CASE:
A securities class action has been filed against Mylan N.V. (MYL) on behalf of all persons or entities who purchased or otherwise acquired Mylan publicly traded securities between May 9, 2018 through May 6, 2019. This case has been filed in the USDC – Pennsylvania (Western).
The Complaint alleges that Mylan made false and/or misleading statements and/or failed to disclose that: (1) Mylan’s Morgantown facility was in significant violation of the FDA’s Current Good Manufacturing Practice regulations; (2) Mylan would need to engage in a massive restructuring and remediation program; (3) Mylan’s North American Segment would be substantially impacted by said program, which would in turn materially impact Mylan’s financial health; (3) Mylan lacked effective internal control over financial reporting; and (4) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.